2589-11-9

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-3H-imidazo[4,5-c]pyridine is utilized as a key intermediate in the development and synthesis of various pharmaceutical drugs. Its unique chemical structure and reactivity make it a valuable component in creating new and effective medications.
Used in Drug Synthesis:
6-Chloro-3H-imidazo[4,5-c]pyridine serves as a versatile building block in the synthesis of a wide range of pharmaceutical compounds. Its ability to form stable bonds with other molecules allows for the creation of innovative and potent drugs with diverse therapeutic applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 6-Chloro-3H-imidazo[4,5-c]pyridine is employed as a research tool to explore new drug candidates and understand the structure-activity relationships of potential therapeutic agents. Its unique properties enable scientists to investigate novel drug targets and develop more effective treatments for various diseases.

Upstream product

• 2604-39-9 4-amino-2-chloro-5-nitropyridine 
• 89182-17-2 6-chloro-pyridine-3,4-diamine 
• 64-18-6 formic acid 
• 122-51-0 orthoformic acid triethyl ester 
• 14036-06-7 diethoxymethyl acetate 

Downstream Products

• 1445856-54-1 6-chloro-3-(4-methoxybenzyl)-3H-imidazo[4,5-c]pyridine 
• 1445856-55-2 6-(1-ethoxyvinyl)-3-(4-methoxybenzyl)-3H-imidazo[4,5-c]pyridine 
• 1445856-56-3 1-(3-(4-methoxybenzyl)-3H-imidazo[4,5-c]pyridin-6-yl)ethanone 
• 1445856-57-4 1-(3-(4-methoxybenzyl)-3H-imidazo[4,5-c]pyridin-6-yl)ethanone oxime 
• 1445856-53-0 1-(3-(4-methoxybenzyl)-3H-imidazo[4,5-c]pyridin-6-yl)ethanamine 
• 1445856-79-0 N⁴-(5-cyclopropyl-1H-pyrazol-3-yl)-N²-(1-(3-(4-methoxybenzyl)-3H-imidazo[4,5-c]pyridin-6-yl)ethyl)pyrimidine-2,4-diamine 

Relevant academic research and scientific papers

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I wherein A, Rla, Rlb, R2, R3, R4, R5, R6, R7, Rs, Ra, Rb, X1, X2, X3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders

A simple and convenient two-step, one-pot synthesis of hetero-imidazoles from nitroaminoaryls catalyzed by Ytterbium triflate

A mild two-step one-pot procedure for the conversion of ortho-nitroamino aromatic heterocycles into corresponding benzo and heteroaromatic fused imidazoles is described. The procedure utilizes iron powder, acetic acid, triethylorthoformate, and a catalytic amount of Ytterbium triflate at 75 C for the nitro group reduction and cyclization reaction. The optimum stoichiometry of each component is highlighted and the broad utility is demonstrated with high compatibility to numerous functional groups.

Mild and general one-pot reduction and cyclization of aromatic and heteroaromatic 2-nitroamines to bicyclic 2 H -imidazoles

A one-pot procedure for the conversion of aromatic and heteroaromatic 2-nitroamines into bicyclic 2H-benzimidazoles is described. The procedure employs formic acid, iron powder, and an additive such as NH4Cl to reduce the nitro group and effect the imidazole cyclization with high-yielding conversions generally within one to two hours. The compatibility with a wide range of functionality demonstrates the general utility of this procedure.

Thiophene-imidazopyridines

The invention relates to thiophene-imidazopyridine compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of PIk1